| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Glioblastoma is the most malignant primary brain tumor in humans. The patinets with glioblastoma have a uniformly poor prognosis. The significance of targeting glioblastoma-stem cells may be important for successful treatment. In this study, we analyzed the efficacy of the Nothc inhibitor and Akt inhibitor for glioblastoma stem cell with Notch inhibitor resistance. Notch inhibitor concomitant Akt inhibitor treatment enhanced the effect by monothearapy such as suppression of cell proliferation and stemness maintenance, and promotion of apoptosis.
|
